Hurvitz Chaim

SEC source: 0001415889-25-024082 · form4-09102025_070956.xml · derivative · entry 1

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-04-09

F1 · price: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer.

F1 · derivative.exercise_date: Represents stock options ("Options") granted pursuant to the Issuer's 2021 Omnibus Incentive Plan. The Options shall vest on April 9, 2026, subject to continued service to the Issuer.

SEC source: 0001213900-24-055829 · ownership.xml · derivative · entry 1

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,122,239

Underlying: Common Stock · 21,122,239 shares

Expires 2034-06-17

F1 · derivative.exercise_date: The stock options vested fully upon the date of grant.

SEC source: 0001415889-23-013137 · form4-09112023_010907.xml · nonDerivative · entry 1

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 570,000

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

SEC source: 0001387131-23-011682 · hurvitz_form4-092723.xml · derivative · entry 2

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 42,417,309

Underlying: Common Stock · 42,417,309 shares

Expires not disclosed

F7 · price: Pursuant to a Warrant Exchange Agreement, dated August 14, 2023, between the Company and the reporting person, simultaneously with the Share Exchange, warrants to purchase 7,109 ordinary shares of Private Dror held by Shirat Hachaim, representing all warrants to purchase ordinary shares of Private Dror beneficially owned by the reporting person, were cancelled, and the Company issued to Shirat Hachaim warrants to purchase shares of the Company's Common Stock with an exercise price of $0.033 per share.

F5 · derivative.exercise_date: Warrants will be exercisable from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the warrants (the "Initial Exercise Date").

F6 · derivative.expiration_date: Warrants expire on the fifth anniversary of the Initial Exercise Date.

F4 · ownership.nature: The securities are held by Shirat Hachaim, an entity of which the reporting person is the sole owner and over whose shares the reporting person has sole voting and dispositive power .

SEC source: 0001387131-23-011682 · hurvitz_form4-092723.xml · derivative · entry 1

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 592,150.79

Underlying: Common Stock · 59,215,079 shares

Expires not disclosed

F3 · price: Pursuant to a Share Exchange Agreement, dated July 5, 2023 (as amended, the "Share Exchange Agreement"), by and among the Company, Dror Ortho-Design Ltd. ("Private Dror"), and the shareholders of Private Dror, Shirat Hachaim Ltd ("Shirat Hachaim") transferred 16,103 ordinary shares of Private Dror, representing all ordinary shares of Private Dror beneficially owned by the reporting person, to the Company in exchange for shares of Preferred Stock (the "Share Exchange").

F1 · derivative.exercise_date: Shares of Series A Convertible Preferred Stock, par value $0.0001 per share and with a stated value of $1.10 per share (the "Preferred Stock") of Dror Ortho-Design, Inc. (formerly Novint Technologies, Inc.) (the "Company") shall be convertible, at any time and from time to time at the option of the Holder thereof, into shares of the company's common stock, par value $0.0001 per share (the "Common Stock") from and after the date the Company has reserved shares of Common Stock on behalf of the holders of the Preferred Stock.

F2 · derivative.expiration_date: The Preferred Stock is perpetual and therefore has no expiration date.

F4 · ownership.nature: The securities are held by Shirat Hachaim, an entity of which the reporting person is the sole owner and over whose shares the reporting person has sole voting and dispositive power .

SEC source: 0000950142-22-003233 · es220307158_4-hurvitz.xml · nonDerivative · entry 3

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

F3 · price: The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common

SEC source: 0000950142-22-003250 · es220307715_4a-hurvitz.xml · nonDerivative · entry 3

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

F3 · price: The original Form 4 disclosed that the price reported in Column 4 is a weighted average price. This Form 4/A is being filed to amend such information. The shares were purchased in a single transaction at $1.10.

SEC source: 0000950142-22-003233 · es220307158_4-hurvitz.xml · nonDerivative · entry 2

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 459,592

F2 · price: The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

SEC source: 0000950142-22-003250 · es220307715_4a-hurvitz.xml · nonDerivative · entry 2

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 459,592

F2 · price: The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.01. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

SEC source: 0000950142-22-003233 · es220307158_4-hurvitz.xml · nonDerivative · entry 1

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,812

F1 · price: The price reported above reflects the weighted average purchase price per share of common stock (the "Common Stock"), of NRx Pharmaceuticals, Inc. (the "Issuer"). The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

SEC source: 0000950142-22-003250 · es220307715_4a-hurvitz.xml · nonDerivative · entry 1

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,812

F1 · price: The price reported in Column 4 is a weighted average price. The original Form 4 did not disclose the range of prices that the shares were purchased pursuant to this transaction. This Form 4/A is being filed to include such ranges. These shares were purchased in multiple transactions at prices ranging from $1.00 to $0.93. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.

SEC source: 0000950142-22-003233 · es220307158_4-hurvitz.xml · derivative · entry 6

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 381,083

Underlying: Common Stock · 162,660 shares

Expires 2032-10-21

F4 · price: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer.

F4 · derivative.exercise_date: Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer.

SEC source: 0000950142-21-001942 · es210157187_4-hurvitz.xml · derivative · entry 3

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 218,423

Underlying: Common Stock · 218,423 shares

Expires 2021-09-01

F5 · price: Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement).

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a "Substitute Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement).

F3 · ownership.nature: Held by Shirat HaChaim Ltd. of which the Reporting Person is the sole owner.

SEC source: 0000950142-21-001942 · es210157187_4-hurvitz.xml · nonDerivative · entry 2

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 208,443

F1 · price: On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement).

F2 · price: The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger.

F4 · ownership.nature: Held by CH Health-Private Venture Capital Ltd. of which the Reporting Person is the sole owner.

SEC source: 0000950142-21-001942 · es210157187_4-hurvitz.xml · nonDerivative · entry 1

Hurvitz Chaim · CIK 0001630542 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,436,350

F1 · price: On May 24, 2021, pursuant to that certain Agreement and Plan of Merger dated December 13, 2020 (the "Merger Agreement") among NRX Pharmaceuticals, Inc. (f/k/a Big Rock Partners Acquisition Corp) (the "Issuer"), Big Rock Merger Corp., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and NeuroRx, Inc. ("NeuroRx"), Merger Sub merged with and into NeuroRx (the "Merger"), with NeuroRx surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of NeuroRx common stock was automatically converted into the right to receive a pro rata portion of 50,000,000 shares of the Issuer's common stock and the contingent right to receive a pro rata portion of 25,000,000 shares of the Issuer's common stock (the "Earnout Shares") and Earnout Cash (as defined in the Merger Agreement).

F2 · price: The Merger Agreement provides that the former shareholders of NeuroRx will receive a pro rata portion of the Earnout Shares if, prior to December 31, 2022, the NeuroRx COVID-19 Drug (i.e., ZYESAMI) receives emergency use authorization by the Food and Drug Administration (the ?FDA?) and NeuroRx submits and the FDA files for review a new drug application for the NeuroRx COVID-19 Drug (i.e., ZYESAMI) (the "Earnout Shares Milestone"). The Reporting Person?s right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on May 24, 2021, the effective date of the Merger.

F3 · ownership.nature: Held by Shirat HaChaim Ltd. of which the Reporting Person is the sole owner.